ethyl-(2-diethoxyphosphoryl-ethyl)-malonic acid diethyl ester | 109496-21-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl-(2-diethoxyphosphoryl-ethyl)-malonic acid diethyl ester
• 英文别名: Aethyl-(2-diaethoxyphosphoryl-aethyl)-malonsaeure-diaethylester
• CAS: 109496-21-1
• 化学式: C₁₅H₂₉O₇P
• 分子量: 352.365
• InChiKey: MUVHZCUITFLQLG-UHFFFAOYSA-N

物化性质

• 沸点：
  162 °C(Press: 2.5 Torr)
• 密度：
  1.0925 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  3.17
• 重原子数：
  23.0
• 可旋转键数：
  12.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  88.13
• 氢给体数：
  0.0
• 氢受体数：
  7.0

反应信息

• 作为产物：
  描述：

  乙烯基磷酸二乙酯 、 乙基丙二酸二乙酯 在 乙醇 、 sodium ethanolate 作用下， 生成 ethyl-(2-diethoxyphosphoryl-ethyl)-malonic acid diethyl ester
  参考文献：
  名称：

  Prevalence and Impact of Medical Comorbidity in Alzheimer's Disease

  摘要：

  Background, We examined the prevalence of comorbid medical illnesses in Alzheimer's disease (AD) patients at different severity levels. We examined the effect of cumulative medical comorbidity on cognition and function,Methods. Analyses of data from 679 AD patients (Mini-Mental State Exam score range 0-30, mean +/- SD = 11.8 +/- 8) from 13 site, (four dementia centers assessing outpatients. four managed care organizations two assisted living facilities, and three nursing homes) prospectively recruited using a stratification approach including dementia severity and care setting Medical comorbidity was quantified tiding the Cumulative Illness Rating Scale-Geriatric.Results. Across patients. 61% had three or more comorbid medical illnesses. Adjusting for age, gender. race. and care C setting. medical comorbidity increased with dementia severity (mild to moderate. p < .01: moderate to severe, p < .001), Adjusting for age. educational level. gender, race. and care setting, higher medical comorbidity was associated with greater impairment in cognition (p < .001) and in self-care (p < .001),Conclusions. Despite the limitation of a cross-sectional design, Our initial findings suggest that there is a strong association between medical comorbidity and cognitive status in AD, Optimal management of medical illness may offer potential to improve cognition in AD.

  DOI：

  10.1093/gerona/57.3.m173

文献信息

• Pudowik; Grischina, Zhurnal Obshchei Khimii, 1953, vol. 23, p. 267,272; engl. Ausg. S. 277, 281
  作者：Pudowik、Grischina

  DOI：——

  日期：——